Skip to main content

Sanofi to slash U.S. insulin prices in 2024 after similar cuts by Eli Lilly and Novo Nordisk

The French drugmaker is the last major insulin manufacturer to try to head off government efforts to cap monthly costs by announcing its own steep price cuts.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.